Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04501250
Recruitment Status : Completed
First Posted : August 6, 2020
Last Update Posted : August 6, 2020
Sponsor:
Information provided by (Responsible Party):
Geropharm

Brief Summary:
Сomparative pharmacokinetic study of Rinsulin® NPH, suspension for subcutaneous administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, suspension for subcutaneous administration, 100 IU/ml (Lilly France, France) using the euglycemic hyperinsulinemic clamp.

Condition or disease Intervention/treatment Phase
Pharmacokinetics Bioequivalence Drug: Rinsulin NPH Drug: Humulin NPH Not Applicable

Detailed Description:
A double-blinded, randomized, comparative, crossover pharmacokinetics study of Rinsulin® NPH, suspension for subcutaneous administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, suspension for subcutaneous administration, 100 IU/ml (Lilly France, France) using method of euglycemic hyperinsulinemic clamp on healthy volunteers

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Crossover Assignment two-way crossover
Masking: Double (Participant, Investigator)
Masking Description: A double-blinded
Primary Purpose: Basic Science
Official Title: A Double-blinded, Randomized, Comparative, Crossover Pharmacokinetics Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using Method of Euglycemic Hyperinsulinemic Clamp on Healthy Volunteers
Actual Study Start Date : October 23, 2017
Actual Primary Completion Date : January 1, 2018
Actual Study Completion Date : May 21, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rinsulin® NPH
Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
Drug: Rinsulin NPH
subcutaneous injection at a dose of 0.4 IU/kg

Drug: Humulin NPH
subcutaneous injection at a dose of 0.4 IU/kg

Active Comparator: Humulin® NPH
Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
Drug: Rinsulin NPH
subcutaneous injection at a dose of 0.4 IU/kg

Drug: Humulin NPH
subcutaneous injection at a dose of 0.4 IU/kg




Primary Outcome Measures :
  1. Смах [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Test Drug Observed Maximum Plasma Concentration (Cmax)

  2. AUC 0-12 [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Total area under the curve "drug concentration - time" in the time interval from 0 to 12 h

  3. AUC GIR 0-12 [ Time Frame: -2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour ]
    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h

  4. AUC GIR 0-24 [ Time Frame: -2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour ]
    Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 24 h

  5. GIRmax [ Time Frame: -2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour ]
    Maximum glucose infusion rate over the study period

  6. tGIRmax [ Time Frame: -2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour ]
    Time to reach maximum glucose infusion rate

  7. tGIRlag [ Time Frame: -2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour ]
    Time between the drug administration and the onset of action


Secondary Outcome Measures :
  1. AUC 0-2 [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h

  2. AUC 0-6 [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h

  3. AUC 0-24 [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Total area under the curve "drug concentration - time" in the time interval from 0 to 24 h

  4. AUC 0-∞ [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Total area under the curve "drug concentration - time" in the time interval from 0 to ∞

  5. Tmax [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Time to reach test drug Maximum Plasma Concentration

  6. T1/2 [ Time Frame: - 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours ]
    Half-life of a drug tested



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent to participate in the study.
  • Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
  • Age 18-50, inclusive.
  • Body mass index 18.5 - 27 kg / m2.
  • Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.
  • Consent to all restrictions imposed during the study.

Exclusion Criteria:

  • Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.
  • Presence of episodes of hypoglycemia in the history of the volunteer
  • Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.
  • Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.
  • Fasting plasma glucose> 6.1 mmol / L at screening.
  • HbA1C> 6% at the time of screening.
  • Oral glucose tolerance test - blood glucose level ≥7.8 mmol / L (2 hours after glucose loading) during screening.
  • Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.
  • Taking medications, phytopreparations, biologically active additives within 14 days before screening.
  • Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.
  • Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.
  • Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol (incl. a history of mental illness).
  • Presence or history (three years before the the study drug) of narcotic, drug and / or substance abuse.
  • Positive test for the content of narcotic drugs in urine during the screening period.
  • Anamnestic information about alcoholism or taking more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits).
  • Positive test for alcohol in breath during screening.
  • Nicotine addiction (regular use of tobacco less than 6 months before screening).
  • Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening.
  • Burdened allergological history.
  • presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.
  • Presence of oncological diseases within 5 years before the screening.
  • History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).
  • Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.
  • Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.
  • History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04501250


Locations
Layout table for location information
Russian Federation
Yarosslavl Clinical Hospital #3
Yaroslavl, Russian Federation
Sponsors and Collaborators
Geropharm
Investigators
Layout table for investigator information
Principal Investigator: Sergei Mr Noskov, AP of medicine Yaroslavl City Clinical Hospital No. 3
Layout table for additonal information
Responsible Party: Geropharm
ClinicalTrials.gov Identifier: NCT04501250    
Other Study ID Numbers: RINCL-NPH
First Posted: August 6, 2020    Key Record Dates
Last Update Posted: August 6, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Geropharm:
human recombinant insulin
euglycemic hyperinsulinemic clamp
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs